Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

39.14USD
26 May 2017
Change (% chg)

$-0.25 (-0.63%)
Prev Close
$39.39
Open
$39.22
Day's High
$39.30
Day's Low
$38.57
Volume
1,884,595
Avg. Vol
1,782,314
52-wk High
$55.95
52-wk Low
$30.80

MDCO.O

Chart for MDCO.O

About

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $2,824.61
Shares Outstanding(Mil.): 72.17
Dividend: --
Yield (%): --

Financials

  MDCO.O Industry Sector
P/E (TTM): -- 14.31 17.43
EPS (TTM): -1.93 -- --
ROI: -11.81 -7.26 -5.41
ROE: -21.22 -6.76 -4.69

BRIEF-Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

* Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

May 19 2017

BRIEF-The Medicines Company Q1 loss per share $1.44

* The Medicines Company reports first-quarter 2017 financial results

Apr 26 2017

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

Apr 26 2017

Federal appeals court rules Mylan can proceed with generic Angiomax

A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company .

Apr 06 2017

Federal appeals court rules Mylan can proceed with generic Angiomax

A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company.

Apr 06 2017

UPDATE 1-Federal appeals court rules Mylan can proceed with generic Angiomax

April 6 A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company.

Apr 06 2017

BRIEF-The Medicines Company appoints Paris Panayiotopoulos to its board

* The medicines company appoints Paris Panayiotopoulos to its board of directors

Mar 31 2017

Medicines Co drug shows long-term cholesterol lowering in study

WASHINGTON A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday.

Mar 17 2017

Medicines Co drug shows long-term cholesterol lowering in study

WASHINGTON, March 17 A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday.

Mar 17 2017

BRIEF-Medicines Co reports Q4 loss per share $1.77 from continuing operations

* The Medicines Company reports fourth-quarter and full-year 2016 financial results

Feb 28 2017

More From Around the Web

Earnings vs. Estimates